Department of Immunology, University Hospital Zurich, 8091, Zurich, Switzerland.
Faculty of Medicine, University of Zurich, 8006, Zurich, Switzerland.
Cell Mol Life Sci. 2018 Nov;75(22):4163-4176. doi: 10.1007/s00018-018-2908-7. Epub 2018 Aug 23.
The recent impact of cancer immunotherapies has firmly established the ability and importance of the immune system to fight malignancies. However, the intimate interaction between the highly dynamic tumor and immune cells leads to a selection process driven by genetic and epigenetic processes. As the molecular pathways of cancer resistance mechanisms to immunotherapy become increasingly known, novel therapeutic targets are being tested in combination with immune-stimulating approaches. We here review recent insights into the molecular mechanisms of tumor resistance with particular emphasis on epigenetic processes and place these in the context of previous models.
最近癌症免疫疗法的影响有力地确立了免疫系统对抗恶性肿瘤的能力和重要性。然而,高度动态的肿瘤细胞和免疫细胞之间的密切相互作用导致了一个受遗传和表观遗传过程驱动的选择过程。随着癌症对免疫疗法的耐药机制的分子途径越来越被了解,新的治疗靶点正在与免疫刺激方法联合进行测试。我们在这里回顾了肿瘤耐药的分子机制的最新见解,特别强调了表观遗传过程,并将这些放在以前的模型的背景下。